Welcome to our dedicated page for Therapeuticsmd news (Ticker: TXMD), a resource for investors and traders seeking the latest updates and insights on Therapeuticsmd stock.
TherapeuticsMD, Inc. (NASDAQ: TXMD) is described in its public communications as a company that owns rights to pharmaceutical royalties and operates as a pharmaceutical royalty company. Its recurring news releases focus on financial results and business updates related to this royalty-based model. Each quarter, the company issues press releases detailing net income or net loss from continuing operations, license revenues primarily associated with the Mayne License Agreement, and total operating expenses from continuing operations.
These earnings announcements highlight how changes in sales of licensed products by TherapeuticsMD’s licensees affect license revenue, and how the company’s transition from a commercializing pharmaceutical business to a royalty-based business has influenced its cost structure. The company frequently discusses reductions in operating expenses, including lower general and administrative costs, and refers to efficiencies realized as a royalty-based business with more limited infrastructure.
Another recurring theme in TherapeuticsMD’s news is its evaluation of strategic alternatives. In multiple press releases, the company states that it is exploring a variety of potential transactions, which may include an acquisition, merger, other business combination, sale of assets, or other strategic transactions involving the company. It also notes that there can be no assurance of any particular outcome and that no timetable has been set for this process.
Visitors to the TXMD news page can review this sequence of financial updates, commentary on the company’s royalty assets, and disclosures about its strategic review process. For investors and followers of TXMD stock, these news items provide insight into the company’s royalty revenue trends, expense profile, and the status of its exploration of possible strategic alternatives over time.
TherapeuticsMD, Inc. (NASDAQ: TXMD) announced its participation in the Stifel 2020 Virtual Healthcare Conference on November 17, 2020, at 9:20 a.m. Eastern time. Investors can access a live webcast of the presentation on the company’s website. TherapeuticsMD focuses on developing innovative products for women's healthcare, addressing issues in family planning, reproductive health, and menopause management. The company aims to enhance women’s health and raise awareness of their healthcare challenges.
TherapeuticsMD (NASDAQ:TXMD) announced the pricing of its public offering of approximately 23.4 million shares, aiming for gross proceeds of $30 million. The offering is set to close around November 12, 2020, pending customary conditions. A 30-day option for underwriters to purchase an additional 3.5 million shares is also granted. The proceeds will fund the commercialization of three FDA-approved products: IMVEXXY, BIJUVA, and ANNOVERA, as well as working capital and general corporate purposes.
TherapeuticsMD, Inc. (NASDAQ:TXMD) has announced an underwritten public offering of its common stock, granting the underwriter a 30-day option to purchase an additional 15% of shares. The proceeds will primarily be used for the commercialization of its three FDA-approved products: IMVEXXY®, BIJUVA®, and ANNOVERA®. Funds will also support working capital and general corporate purposes. Cantor Fitzgerald & Co. is the sole bookrunning manager for this offering.
TherapeuticsMD, Inc. (NASDAQ:TXMD) reported a significant 80% increase in net revenue to $19.3 million for Q3 2020, surpassing estimates for the sixth consecutive quarter. This growth was driven by a 62% rise in product sales to $17.3 million. The company reduced operating expenses by $11.0 million, totaling $37.1 million. Notably, ANNOVERA revenue soared by 250% to $6.4 million, while IMVEXXY and BIJUVA also showed strong performance. The company is exploring the divestiture of vitaCare, potentially unlocking over $50 million in non-dilutive proceeds for shareholders.
TherapeuticsMD Inc. (NASDAQ: TXMD) has partnered with POPSUGAR to launch a new women's health platform called Full Disclosure, which promotes its contraceptive product, ANNOVERA® (segesterone acetate and ethinyl estradiol vaginal system). This innovative platform aims to foster open discussions about women’s health, covering topics like fertility and pregnancy, without stigma. The initiative responds to the growing demand for longer-acting contraceptives, emphasizing ANNOVERA's unique non-invasive application.
TherapeuticsMD, Inc. (NASDAQ:TXMD) emphasizes the necessity for women to consult healthcare providers regarding sexual and reproductive health options. The company promotes treatments such as ANNOVERA and IMVEXXY through awareness campaigns. Recently, ANNOVERA garnered increased demand across various distribution channels. In recognition of Menopause Awareness Month, TherapeuticsMD launched a series aimed at improving discussions surrounding menopause and its symptoms. The company continues to advocate for women's healthcare and communication with providers.